Metformin administration improves endothelial function in women with polycystic ovary syndrome
Metformin administration improves endothelial function in women with polycystic ovary syndrome
复制标题
DOI：
10.1530/eje.1.01910
复制
发表时间：
2005-05-01
影响因子：
5.8
通讯作者：
Mavrikakis, M
中科院分区：
文献类型：
--
作者：
Diamanti-Kandarakis, E;Alexandraki, K;Mavrikakis, M
目的：本研究的目的是探讨多囊卵巢综合征（PCOS）的年轻女性的内皮状态，使用一种简单，易于重现的血流动力学方法结合生物标志物，并评估二甲双胍治疗对这些参数的影响。设计：描述性临床试验。方法：40名年轻女性，20名PCOS和20名正常女性相似的年龄和体重指数进行了研究。PCOS组给予美托洛尔1700 mg/d，疗程6个月。通过肱动脉血流介导的扩张（FMD）和血浆内皮素-1（ET-1）水平的测量，研究了两组以及二甲双胍治疗后的内皮状态、代谢和激素水平。与对照组相比，PCOS组的FMD受损（分别为3.24 ± 0.71%和8.81 ± 1.07%，P < 0.0001），但二甲双胍治疗后该差异恢复正常（二甲双胍治疗后的PCOS vs对照组：8.17 +/- 1.26 vs 8.81 +/-1.07%，P = 0.70），因为二甲双胍治疗后的数值显著改善（二甲双胍治疗后的PCOS VS二甲双胍治疗后的PCOS：3.24 +/- 0.71 vs 8.17 +/-1.26%，P = 0.003）。PCOS组ET-1水平明显高于对照组（7.23 ± 0.50 vs 4.99 ± 0.69 fmol/l，P = 0.01），二甲双胍治疗后显著改善（PCOS-二甲双胍vs PCOS-二甲双胍后：7.23 +/- 0.50 vs 3.57 +/- 0.60 fmol/l，P < 0.0001），与对照组相比，其差异逆转（二甲双胍后与对照组的PCOS：3.57 +/- 0.60 vs 4.99 +/- 0.69fmol/l，P = 0.13）。二甲双胍给药改善了高雄激素血症。然而，在这项研究中，用于评估胰岛素抵抗的数学方法未能显示任何检测到的改变后，治疗与metformin.Conclusions：PCOS妇女被发现表现出内皮功能障碍与对照组相比，这是扭转6个月后，二甲双胍管理。
Objective: The aim of this study was to investigate the endothelial status in young women with polycystic ovary syndrome (PCOS), using a simple and easily reproducible hemodynamic method combined with a biological marker and to evaluate the effect of metformin treatment on these parameters.Design: Descriptive clinical trial.Methods: Forty young women, 20 with PCOS and 20 normal women of similar age and body mass index were studied. Metformin (1700 mg daily) was administered for 6 months to the PCOS group. The endothelium status and the metabolic and hormonal profile were studied in both groups, as well as after metformin, by flow-mediated dilatation (FMD) on the brachial artery and by measurements of plasma endothelin-1 (ET-1) levels.Results: FMD was impaired in the PCOS group when compared with controls (3.24 +/- 0.71%, vs 8.81 +/- 1.07% respectively, P < 0.0001), but this difference normalized after metformin treatment (PCOSpost-metformin vs controls: 8.17 +/- 1.26 vs 8.81 +/- 1.07%, P = 0.70) since the values significantly improved after metformin treatment (PCOSpre-metformin VS PCOSpost-metformin: 3.24 +/- 0.71 vs 8.17 +/- 1.26%, P = 0.003). ET-1 levels were significantly higher in the PCOS women compared with the control group (7.23 +/- 0.50 vs 4.99 +/- 0.69 fmol/l, P = 0.01), they improved significantly after metformin treatment (PCOSpre-metformin vs PCOSpost-metformin: 7.23 +/- 0.50 vs 3.57 +/- 0.60 fmol/l, P < 0.0001) and their difference compared with the control group was reversed (PCOSpost-metformin vs controls: 3.57 +/- 0.60 vs 4.99 +/- 0.69fmol/l, P = 0.13). Metformin administration improved hyperandrogenemia. However, in this study, mathematical methods used to assess insulin resistance failed to show any detected alteration after treatment with metformin.Conclusions: PCOS women were found to exhibit endothelial dysfunction compared with controls, which was reversed 6 months after metformin administration.